Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study.
Mery B, Ménétrier-Caux C, Montané L, Heudel PE, Ray-Coquard I, Bachelot T, Derbel O, Augereau P, Treilleux I, Berthet J, Nkodia A, Bardin-Dit-Courageot C, Attignon V, Ferrari A, Garin G, Perol D, Caux C, Dubois B, Trédan O. Mery B, et al. Among authors: bardin dit courageot c. Breast Cancer (Dove Med Press). 2023 Apr 27;15:311-325. doi: 10.2147/BCTT.S400055. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37139242 Free PMC article.
Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.
Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C. Trédan O, et al. Among authors: bardin dit courageot c. Eur J Cancer. 2013 May;49(7):1673-82. doi: 10.1016/j.ejca.2012.11.028. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265706
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C. Trédan O, et al. Among authors: bardin dit courageot c. Ann Oncol. 2015 Jul;26(7):1353-62. doi: 10.1093/annonc/mdv173. Epub 2015 Apr 7. Ann Oncol. 2015. PMID: 25851629 Free article. Clinical Trial.
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.
Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N'Kodia A, Bardin-Dit-Courageot C, Rigal C, Pérol D, Caux C, Ménétrier-Caux C. Verronèse E, et al. Among authors: bardin dit courageot c. Oncoimmunology. 2015 Nov 10;5(3):e1100791. doi: 10.1080/2162402X.2015.1100791. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141361 Free PMC article.
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-Dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C. Trédan O, et al. Among authors: bardin dit courageot c. Ann Oncol. 2018 Feb 1;29(2):523. doi: 10.1093/annonc/mdx058. Ann Oncol. 2018. PMID: 28368453 Free article. No abstract available.